Search

Your search keyword '"Chang, Lauren A."' showing total 132 results

Search Constraints

Start Over You searched for: Author "Chang, Lauren A." Remove constraint Author: "Chang, Lauren A."
132 results on '"Chang, Lauren A."'

Search Results

1. Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity

4. Big Streamlining For Small Subdivision Developers

5. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

6. Ally, adversary, or arbitrator? The context-dependent role of eosinophils in vaccination for respiratory viruses and subsequent breakthrough infections.

7. Enhanced mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.

8. Plitidepsin as an Immunomodulator against Respiratory Viral Infections

9. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

10. Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters

11. Host immune responses associated with SARS-CoV-2 Omicron infection result in protection or pathology during reinfection depending on mouse genetic background.

12. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

13. Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity.

14. Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity

17. Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian Hamsters

20. SARS-CoV-2 Ancestral and Variant of Concern Breakthrough infections boost both cross-reactive cellular and humoral immune responses in mRNA-vaccinated Hamsters.

21. Influenza breakthrough infection in vaccinated mice is characterized by nonpathological lung eosinophilia.

22. A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine

25. Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine

27. Recurrent respiratory syncytial virus infection in a CD14 deficient patient

29. Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient

30. Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine

32. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

33. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

34. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge

35. T Lymphocyte-Directed Gene Therapy for ADA$^-$ SCID: Initial Trial Results After 4 Years

38. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

39. Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

40. Prefrontal executive function and [D.sub.1], [D.sub.3], 5-[HT.sub.2A] and 5-[HT.sub.6] receptor gene variations in healthy adults

41. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

42. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

43. SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

44. Molecular Dissection Of Human Antibody Responses Following Prefusion-Stabilized RSV F Vaccination

45. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years

47. Epitope-Specific Serological Assays for RSV: Conformation Matters

50. A proof of concept for structure-based vaccine design targeting RSV in humans.

Catalog

Books, media, physical & digital resources